Aerie Pharmaceuticals (AERI) : Traders are bullish on Aerie Pharmaceuticals (AERI) as it has outperformed the S&P 500 by a wide margin of 85.85% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 72.56%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 73.48% in the last 1 week, and is up 82.09% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 72.5% and the 50-Day Moving Average is 85.3%.The 200 Day SMA reached 97.63% Aerie Pharmaceuticals, Inc. is up 93.83% in the last 3-month period. Year-to-Date the stock performance stands at 43.2%.
Aerie Pharmaceuticals (AERI) has been rated by 6 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $55 and the lowest price target forecast is $44. The average forecast of all the analysts is $48.33 and the expected standard deviation is $3.93.
For the current week, the company shares have a recommendation consensus of Buy. Aerie Pharmaceuticals (NASDAQ:AERI): The stock opened at $31.01 and touched an intraday high of $35.25 on Friday. During the day, the stock corrected to an intraday low of $30.9, however, the bulls stepped in and pushed the price higher to close in the green at $34.87 with a gain of 13.92% for the day. The total traded volume for the day was 10,250,248. The stock had closed at $34.87 in the previous trading session.
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Companys primary product candidates, triple-action Rhopressa and quadruple-action Roclatan, are once-daily eye drops. The Companys product candidate, once-daily, quadruple-action Roclatan, is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET), which are both biochemical targets for lowering intraocular pressure (IOP). The Companys Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533, its second-generation ROCK/NET inhibitor.